FAILED TRIAL: Ph 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer failed to meet primary endpoint of PFS improvement August 9, 2023
Jemperli (dostarlimab) + chemo approved in the US as 1L treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer August 9, 2023
Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization Announced August 2, 2023
Ph 3 KEYNOTE-A18 Trial Met Primary Endpoint of PFS in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer July 27, 2023
Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer Announced July 11, 2023
Supplemental BLA accepted for priority review for Jemperli + chemo For The Treatment of dMMR/MSI-H Primary Advanced Or Recurrent Endometrial Cancer June 14, 2023
Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors June 6, 2023
Lynparza + Imfinzi reduced risk of disease progression or death by 37% vs. chemo + Avastin in ovarian cancer patients without tumour BRCA mutations in the DUO-O Ph 3 trial June 6, 2023
IMFINZI + LYNPARZA and IMFINZI alone both significantly improved PFS in advanced endometrial cancer when added to chemotherapy May 31, 2023
ELAHERE® Demonstrates OS Benefit in the Ph 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer May 10, 2023
EMA Validates MAA for Jemperli (dostarlimab) + Chemo for the Treatment of dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer May 10, 2023
Positive final results from Ph 2 trial of VB10.16 + atezolizumab in advanced cervical cancer announced April 27, 2023
Initiation of Ph 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma announced April 20, 2023
Lynparza and Imfinzi combination improved PFS in newly diagnosed patients with advanced ovarian cancer without tumour BRCA mutations in DUO-O Ph 3 trial April 12, 2023
Interim results from Part 1 of Ph 3 RUBY trial of Jemperli + chemo in adult patients with primary advanced or recurrent endometrial cancer announced April 6, 2023
KEYTRUDA + Chemo Significantly Improved PFS vs chemo Alone as 1L Therapy for Advanced/Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status April 6, 2023
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01; DisTinGuish Trial of DKN-01 + tislelizumab & chemo to continue as a clinical collaboration March 31, 2023
Results from INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrate Deep and Durable Responses in Platinum Resistant Ovarian Cancer March 31, 2023
KEYTRUDA + Chemo Significantly Improved PFS vs chemo Alone as 1L Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of MMR Status March 31, 2023
